131 related articles for article (PubMed ID: 38874670)
21. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.
Salaffi F; Ciapetti A; Carotti M; Gasparini S; Citera G; Gutierrez M
Health Qual Life Outcomes; 2014 Aug; 12():129. PubMed ID: 25146299
[TBL] [Abstract][Full Text] [Related]
22. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
23. Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis.
Huang Y; Chen Y; Liu T; Lin S; Yin G; Xie Q
PLoS One; 2020; 15(12):e0244788. PubMed ID: 33382842
[TBL] [Abstract][Full Text] [Related]
24. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
van der Heijde D; Sieper J; Maksymowych WP; Lambert RG; Chen S; Hojnik M; Anderson JK; Pangan AL
Arthritis Res Ther; 2018 Mar; 20(1):61. PubMed ID: 29587851
[TBL] [Abstract][Full Text] [Related]
25. Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry.
Akgul O; Bodur H; Ataman S; Yurdakul FG; Capkin E; Gurer G; Sezer I; Duruoz MT; Melikoglu MA; Cay HF; Rezvani A; Yagci I; Gogus F; Kamanli A; Cevik R
Rheumatol Int; 2020 Nov; 40(11):1793-1801. PubMed ID: 32814986
[TBL] [Abstract][Full Text] [Related]
26. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
[TBL] [Abstract][Full Text] [Related]
27. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.
Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Lenaerts J; van den Bosch F; Wei JC; Pedersen R; Bonin R; Jones H; Marshall L; Logeart I; Vlahos B; Bukowski JF; Maksymowych WP
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1590-1598. PubMed ID: 28482137
[TBL] [Abstract][Full Text] [Related]
28. Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis.
Khoury G; Combe B; Morel J; Lukas C
Clin Exp Rheumatol; 2021; 39(2):242-252. PubMed ID: 33506749
[TBL] [Abstract][Full Text] [Related]
29. The relationship between clinical parameters and ultrasonographic enthesitis assessment in patients with spondyloarthritis.
Er G; Palamar D; Akgün K; Asoğlu İ; Sarı H
Arch Rheumatol; 2024 Jun; 39(2):242-254. PubMed ID: 38933722
[TBL] [Abstract][Full Text] [Related]
30. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
Kilic E; Kilic G; Akgul O; Ozgocmen S
Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
[TBL] [Abstract][Full Text] [Related]
31. Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index in Turkish patients with ankylosing spondylitis: relationship with disease activity and quality of life.
Zahiroglu Y; Ulus Y; Akyol Y; Tander B; Durmus D; Bilgici A; Kuru O
Int J Rheum Dis; 2014 Feb; 17(2):173-80. PubMed ID: 24576273
[TBL] [Abstract][Full Text] [Related]
32. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
[TBL] [Abstract][Full Text] [Related]
34. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
[TBL] [Abstract][Full Text] [Related]
35. Adherence, Efficacy, and Safety of Wearable Technology-Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial.
Wang Y; Liu X; Wang W; Shi Y; Ji X; Hu L; Wang L; Yin Y; Xie S; Zhu J; Zhang J; Jiao W; Huang F
J Med Internet Res; 2022 Jan; 24(1):e29703. PubMed ID: 35040798
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
Deodhar A; van der Heijde D; Sieper J; Van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Ostor A; Combe B; Sui Y; Chu AD; Song IH
Arthritis Rheumatol; 2022 Jan; 74(1):70-80. PubMed ID: 34196498
[TBL] [Abstract][Full Text] [Related]
37. Both ASDAS and ADC are associated with spinal mobility in active axial spondyloarthritis: A comparison between early and later disease.
Chung HY; Chan SCW; Lee KH; Tsang HHL; Ng LL; Lau CS
Int J Rheum Dis; 2022 Mar; 25(3):317-326. PubMed ID: 35019230
[TBL] [Abstract][Full Text] [Related]
38. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Levitova A; Hulejova H; Spiritovic M; Pavelka K; Senolt L; Husakova M
Arthritis Res Ther; 2016 Nov; 18(1):275. PubMed ID: 27887637
[TBL] [Abstract][Full Text] [Related]
39. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
Sieper J; van der Heijde D; Dougados M; Brown LS; Lavie F; Pangan AL
Ann Rheum Dis; 2012 May; 71(5):700-6. PubMed ID: 22128084
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.
Akkoç N; Arteaga CH; Auteri SE; Betts M; Fahrbach K; Kim M; Kiri S; Neupane B; Gaffney K; Mease PJ
Rheumatol Ther; 2023 Apr; 10(2):307-327. PubMed ID: 36633815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
